Loading...
•
Mar 31, 2022
Leap Therapeutics Q1 2022 Earnings Report
Leap Therapeutics reported financial results for Q1 2022.
Key Takeaways
Leap Therapeutics reported a net loss of $10.4 million for the first quarter of 2022. There were no license revenues recognized in the first quarter 2022, as the upfront payment was fully recognized as of December 31, 2021. Cash and cash equivalents totaled $103.2 million at March 31, 2022.
DKN-01 is progressing across multiple tumor types, with initial prostate cancer data to be presented at the ASCO conference.
Updated data readouts from the DisTinGuish study are expected in the second half of the year.
Leap Therapeutics is planning to host an R&D Day in late June to outline the clinical development strategy for DKN-01.
Net Loss was $10.4 million for the first quarter 2022, compared to $9.1 million for the same period in 2021.
Leap Therapeutics
Leap Therapeutics
Forward Guidance
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties.